Taken together, these data suggest that the low expression of BCL2 and high BECN1 expression result in a marked improvement in clinical outcomes, highlighting that BECN1 may represent a positive prognostic marker for DLBCL. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.